# The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study

Berdien E. Oortgiesen,[1] Roshna Azad,[1] Marc H. Hemmelder,[2] Robby E. Kibbelaar,[3] Nic J.G.M. Veeger,[4,5] Joost C. de Vries,[6] Eric N. van Roon,[1,7,#] and Mels Hoogendoorn[6,#]

Correspondence: Berdien.Oortgiesen@znb.nl.

Supplemental file:

Supplementary Figure 1: First-line treatment of MM patients with renal insufficiency in time, based on guidelines published by the Dutch HOVON Myeloma Working Group in the Netherlands.[1,2,3,4] VAD: vincristine, doxorubicin, dexamethasone.

Supplementary Figure 2. Overall survival of MM patients on dialysis treatment in the pre-guideline cohort compared to the post-guideline cohort.

Supplementary Figure 3. Recurrence of *Dialysis Dependence* within 4 years in MM patients initially reaching dialysis independence.

References:

1. *Guideline multiple myeloma by the Dutch HOVON Myeloma Working Group 2005:* De moderne behandeling van het multipel myeloom: een richtlijn van de Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON). Ned Tijdschr Geneeskd 2005;149:808-813.

2. *Guideline multiple myeloma by the Dutch HOVON Myeloma Working Group 2008:* Lokhorst HM, Zweegman S, Kersten MJ et al. Richtlijnen behandeling multipel myeloom anno 2008. Ned Tijdschr Hematol 2008;5:150-156.

3. *Guideline multiple myeloma by the Dutch HOVON Myeloma Working Group 2010:* Sonneveld P, Zweegman S, Vellenga E et al. Guidelines for treatment of plasma cell dyscrasias in 2010. Ned Tijdschr Hematol 2010;7:84-95.

4. *Guideline multiple myeloma by the Dutch HOVON Myeloma Working Group 2017:* Zweegman S, van de Donk NWCJ, Levin M-D et al. Richtlijn behandeling multipel myeloom 2017. http://www.hematologienederland.nl/sites/default/files/richtlijn-mm-behandeling_hovon_20171006_def.pdf#overlay-context=richtlijnen-1, accessed Januari 12, 2018.